Cargando…

National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018

BACKGROUND: This research aimed to evaluate analgesic utilization in public hospitals from 2013 to 2018 by analyzing the procurement data of 793 hospitals in China. METHODS: This study applied a retrospective observational study by using a database of the Chinese Pharmaceutical Association. The fina...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Honghao, Chen, Xianwen, Liu, Xueli, Zhu, He, Yu, Fei, Ung, Carolina Oi Lam, Chan, Wai Sin, Hu, Hao, Han, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147037/
https://www.ncbi.nlm.nih.gov/pubmed/34034830
http://dx.doi.org/10.1186/s40545-021-00325-8
_version_ 1783697537028325376
author Shi, Honghao
Chen, Xianwen
Liu, Xueli
Zhu, He
Yu, Fei
Ung, Carolina Oi Lam
Chan, Wai Sin
Hu, Hao
Han, Sheng
author_facet Shi, Honghao
Chen, Xianwen
Liu, Xueli
Zhu, He
Yu, Fei
Ung, Carolina Oi Lam
Chan, Wai Sin
Hu, Hao
Han, Sheng
author_sort Shi, Honghao
collection PubMed
description BACKGROUND: This research aimed to evaluate analgesic utilization in public hospitals from 2013 to 2018 by analyzing the procurement data of 793 hospitals in China. METHODS: This study applied a retrospective observational study by using a database of the Chinese Pharmaceutical Association. The final dataset covers 30 provinces and municipalities in China, with a total of 793 public hospitals with complete procurement records of analgesics from January 2013 to December 2018. Procurement cost and dosage utilization were analyzed through descriptive trend statistics. RESULTS: From the procurement cost data, analgesics mainly consisted of opioids and non-steroidal anti-inflammatory drugs (NSAIDs), and the annual cost of both types of drugs increased yearly. The 6-year total cost of opioids accounts for 57% (17,800 million CNY), followed by the cost of NSAIDs accounts for 37% (11,400 million CNY). From 2013 to 2018, the annual cost of opioids nearly doubled, while the annual cost of NSAIDs doubled. The total 6-year clinical drug dosage of opioids accounts for 45% (675 million total defined daily dose (DDD)), and the NSAIDs account for 50% (747 million total DDD). From 2013 to 2018, the annual clinical drug dosage of NSAIDs increased by about 0.6 times. The annual clinical drug dosage of opioids has more than doubled. The top three opioid drugs were dezocine injection, remifentanil injection, and sufentanil injection solution. the top three NSAIDs were flurbiprofen injection, parecoxib injection, and celecoxib oral solution. CONCLUSION: In China, analgesics utilization increased rapidly at public hospitals from 2013 to 2018. The utilization of analgesics was highly concentrated in NSAIDs and opioids. Within the two types of analgesics, the main analgesics utilization is also highly concentrated, with some highly risky analgesics. The rational guideline for the utilization of analgesics needs to be established with the support of real-world evidence.
format Online
Article
Text
id pubmed-8147037
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81470372021-05-25 National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018 Shi, Honghao Chen, Xianwen Liu, Xueli Zhu, He Yu, Fei Ung, Carolina Oi Lam Chan, Wai Sin Hu, Hao Han, Sheng J Pharm Policy Pract Research BACKGROUND: This research aimed to evaluate analgesic utilization in public hospitals from 2013 to 2018 by analyzing the procurement data of 793 hospitals in China. METHODS: This study applied a retrospective observational study by using a database of the Chinese Pharmaceutical Association. The final dataset covers 30 provinces and municipalities in China, with a total of 793 public hospitals with complete procurement records of analgesics from January 2013 to December 2018. Procurement cost and dosage utilization were analyzed through descriptive trend statistics. RESULTS: From the procurement cost data, analgesics mainly consisted of opioids and non-steroidal anti-inflammatory drugs (NSAIDs), and the annual cost of both types of drugs increased yearly. The 6-year total cost of opioids accounts for 57% (17,800 million CNY), followed by the cost of NSAIDs accounts for 37% (11,400 million CNY). From 2013 to 2018, the annual cost of opioids nearly doubled, while the annual cost of NSAIDs doubled. The total 6-year clinical drug dosage of opioids accounts for 45% (675 million total defined daily dose (DDD)), and the NSAIDs account for 50% (747 million total DDD). From 2013 to 2018, the annual clinical drug dosage of NSAIDs increased by about 0.6 times. The annual clinical drug dosage of opioids has more than doubled. The top three opioid drugs were dezocine injection, remifentanil injection, and sufentanil injection solution. the top three NSAIDs were flurbiprofen injection, parecoxib injection, and celecoxib oral solution. CONCLUSION: In China, analgesics utilization increased rapidly at public hospitals from 2013 to 2018. The utilization of analgesics was highly concentrated in NSAIDs and opioids. Within the two types of analgesics, the main analgesics utilization is also highly concentrated, with some highly risky analgesics. The rational guideline for the utilization of analgesics needs to be established with the support of real-world evidence. BioMed Central 2021-05-25 /pmc/articles/PMC8147037/ /pubmed/34034830 http://dx.doi.org/10.1186/s40545-021-00325-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shi, Honghao
Chen, Xianwen
Liu, Xueli
Zhu, He
Yu, Fei
Ung, Carolina Oi Lam
Chan, Wai Sin
Hu, Hao
Han, Sheng
National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title_full National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title_fullStr National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title_full_unstemmed National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title_short National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018
title_sort national drug utilization trend of analgesics in china: an analysis of procurement data at 793 public hospitals from 2013 to 2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147037/
https://www.ncbi.nlm.nih.gov/pubmed/34034830
http://dx.doi.org/10.1186/s40545-021-00325-8
work_keys_str_mv AT shihonghao nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT chenxianwen nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT liuxueli nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT zhuhe nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT yufei nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT ungcarolinaoilam nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT chanwaisin nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT huhao nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018
AT hansheng nationaldrugutilizationtrendofanalgesicsinchinaananalysisofprocurementdataat793publichospitalsfrom2013to2018